Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
213 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Indolent Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Indolent Lymphoma - Pipeline Review, H2 2016', provides an overview of the Indolent Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma - The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects - The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Indolent Lymphoma Overview 10 Therapeutics Development 11 Pipeline Products for Indolent Lymphoma - Overview 11 Indolent Lymphoma - Therapeutics under Development by Companies 12 Indolent Lymphoma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Indolent Lymphoma - Products under Development by Companies 16 Indolent Lymphoma - Companies Involved in Therapeutics Development 18 AbbVie Inc 18 Affimed GmbH 19 Altor BioScience Corporation 20 Amgen Inc. 21 Astellas Pharma Inc. 22 Bayer AG 23 Boehringer Ingelheim GmbH 24 Bristol-Myers Squibb Company 25 Celgene Corporation 26 Eli Lilly and Company 27 F. Hoffmann-La Roche Ltd. 28 Gilead Sciences, Inc. 29 Incyte Corporation 30 Infinity Pharmaceuticals, Inc. 31 Juno Therapeutics Inc. 32 MedImmune, LLC 33 Merck & Co., Inc. 34 Merck KGaA 35 Millennium Pharmaceuticals Inc 36 MorphoSys AG 37 Novartis AG 38 Seattle Genetics, Inc. 39 Trillium Therapeutics Inc. 40 Indolent Lymphoma - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Combination Products 42 Assessment by Target 43 Assessment by Mechanism of Action 46 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 AFM-11 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ALT-803 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 bendamustine hydrochloride - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 BI-836826 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 blinatumomab - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 BMS-986016 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 BTH-1677 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 CC-122 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 copanlisib hydrochloride - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 DI-B4 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 duvelisib - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 entospletinib - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 ibrutinib - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 INCB-40093 - Drug Profile 127 Product Description 127 Mechanism Of Action 127 R&D Progress 127 INCB-50465 - Drug Profile 128 Product Description 128 Mechanism Of Action 128 R&D Progress 128 inebilizumab - Drug Profile 129 Product Description 129 Mechanism Of Action 129 R&D Progress 129 inebilizumab + MEDI-0680 - Drug Profile 131 Product Description 131 Mechanism Of Action 131 R&D Progress 131 itacitinib adipate - Drug Profile 132 Product Description 132 Mechanism Of Action 132 R&D Progress 132 JCAR-014 - Drug Profile 135 Product Description 135 Mechanism Of Action 135 R&D Progress 135 JCAR-015 - Drug Profile 138 Product Description 138 Mechanism Of Action 138 R&D Progress 138 JCAR-017 - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 lenalidomide - Drug Profile 146 Product Description 146 Mechanism Of Action 146 R&D Progress 146 LY-3023414 - Drug Profile 160 Product Description 160 Mechanism Of Action 160 R&D Progress 160 MOR-208 - Drug Profile 162 Product Description 162 Mechanism Of Action 162 R&D Progress 162 obinutuzumab - Drug Profile 167 Product Description 167 Mechanism Of Action 167 R&D Progress 167 ofatumumab - Drug Profile 174 Product Description 174 Mechanism Of Action 174 R&D Progress 174 SEA-CD40 - Drug Profile 182 Product Description 182 Mechanism Of Action 182 R&D Progress 182 TAK-659 - Drug Profile 183 Product Description 183 Mechanism Of Action 183 R&D Progress 183 TTI-621 - Drug Profile 184 Product Description 184 Mechanism Of Action 184 R&D Progress 184 venetoclax - Drug Profile 187 Product Description 187 Mechanism Of Action 187 R&D Progress 187 vorinostat - Drug Profile 196 Product Description 196 Mechanism Of Action 196 R&D Progress 196 Indolent Lymphoma - Dormant Projects 200 Indolent Lymphoma - Discontinued Products 202 Indolent Lymphoma - Product Development Milestones 203 Featured News & Press Releases 203 Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society 203 Nov 30, 2015: New Data from Bayer's Portfolio in Oncology to be Presented at ASH 2015 203 Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 203 Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 204 Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 204 Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 206 Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 207 Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 208 Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 210 Appendix 212 Methodology 212 Coverage 212 Secondary Research 212 Primary Research 212 Expert Panel Validation 212 Contact Us 212 Disclaimer 213
List of Tables
Number of Products under Development for Indolent Lymphoma, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Indolent Lymphoma - Pipeline by AbbVie Inc, H2 2016 18 Indolent Lymphoma - Pipeline by Affimed GmbH , H2 2016 19 Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H2 2016 20 Indolent Lymphoma - Pipeline by Amgen Inc., H2 2016 21 Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016 22 Indolent Lymphoma - Pipeline by Bayer AG, H2 2016 23 Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 24 Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 25 Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2016 26 Indolent Lymphoma - Pipeline by Eli Lilly and Company, H2 2016 27 Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 28 Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016 29 Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2016 30 Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 31 Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016 32 Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2016 33 Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2016 34 Indolent Lymphoma - Pipeline by Merck KGaA, H2 2016 35 Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 36 Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2016 37 Indolent Lymphoma - Pipeline by Novartis AG, H2 2016 38 Indolent Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 39 Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H2 2016 40 Assessment by Monotherapy Products, H2 2016 41 Assessment by Combination Products, H2 2016 42 Number of Products by Stage and Target, H2 2016 44 Number of Products by Stage and Mechanism of Action, H2 2016 47 Number of Products by Stage and Route of Administration, H2 2016 50 Number of Products by Stage and Molecule Type, H2 2016 52 Indolent Lymphoma - Dormant Projects, H2 2016 200 Indolent Lymphoma - Dormant Projects (Contd..1), H2 2016 201 Indolent Lymphoma - Discontinued Products, H2 2016 202
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.